US2023165981A1PendingUtilityA1

[161Tb]-BASED RADIOPEPTIDES

Assignee: UNIV BASELPriority: Sep 30, 2021Filed: Sep 29, 2022Published: Jun 1, 2023

Est. expirySep 30, 2041(~15.2 yrs left)· nominal 20-yr term from priority

Inventors:Cristina Müller Roger Schibli Nicolas Philip Van Der Meulen Francesca Borgna Damian Wild Melpomeni Fani

A61K 51/121A61K 47/22A61K 51/088A61K 9/0019A61K 51/083A61K 9/08A61K 47/12A61P 35/00

PatentIndex Score

Cited by

References

Claims

Abstract

A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.

Claims

exact text as granted — not AI-modified

1 . A radiopeptide comprising 
 (a) a radionuclide, wherein the radionuclide is terbium-161,   (b) a chelator of terbium-161, and   (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist.   
     
     
         2 . The radiopeptide of  claim 1 , wherein the somatostatin receptor (SSTR) antagonist is covalently coupled to (b). 
     
     
         3 . The radiopeptide of  claim 1 , wherein the chelator is a cyclic chelator, in particular a macrocyclic chelator. 
     
     
         4 . The radiopeptide of  claim 1 , wherein the chelator is a tetradentate chelator. 
     
     
         5 . The radiopeptide of  claim 4 , wherein the chelator contains four nitrogen atoms. 
     
     
         6 . The radiopeptide of  claim 5 , wherein the chelator is a 12-membered tetraaza ring system. 
     
     
         7 . The radiopeptide of  claim 1 , wherein the chelator comprises at least one substituent containing at least one carboxy function. 
     
     
         8 . The radiopeptide of  claim 1 , wherein the chelator is DOTA or a DOTA derivative. 
     
     
         9 . The radiopeptide of  claim 8 , wherein the DOTA derivative is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       . 
     
     
         10 . The radiopeptide of  claim 9 , wherein the chelator is DOTA (dodecane tetraacetic acid). 
     
     
         11 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist is covalently coupled to the chelator via an amide linkage. 
     
     
         12 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist binds to SSTR-2 (sst2) or is an SSTR-2 (sst2) selective antagonist. 
     
     
         13 . The radiopeptide of  claim 1 , wherein less than 20% of the administered somatostatin receptor antagonist is internalized by cells. 
     
     
         14 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist is a cyclic peptide. 
     
     
         15 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist contains two cysteine residues, which preferably form a disulfide bridge. 
     
     
         16 . The radiopeptide of  claim 15 , wherein the somatostatin receptor antagonist contains the two cysteine residues at peptide positions 2 and 7. 
     
     
         17 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist comprises 8 to 14 amino acids, preferably 8 to 10, more preferably 8 amino acids. 
     
     
         18 . The radiopeptide of  claim 1 , wherein the somatostatin receptor antagonist comprises formula I: X1-cyclo[D-Cys-X3-X4-Lys-Thr-Cys]-D-Tyr-NH 2 , (SEQ ID NO: 1) wherein X1, X3, and X4 are selected from a naturally or a non-naturally occurring D- or L-amino acid. 
     
     
         19 . The radiopeptide of  claim 18 , wherein (i) X1 is selected from the group consisting of naturally occurring Phe or a substituted Phe having one or more substitutions at the phenyl ring system and Cpa, (ii) X3 is selected from the group consisting of Aph(Hor), Leu, L-Agl(NMe.benzoyl), D-Agl(NMe.benzoyl), Aph(Cbm),Tyr, Aph(CONH-OCH 3 ), Tyr, Aph(CONH-OH), and/or (iii) X4 is selected from the group consisting of D-Trp and D-Aph(Cbm) (D-4-amino-Phe(carbamoyl)), wherein X1 is preferably selected from the group consisting of pNOs-Phe, pCl-Pheand Cpa, X3 is preferably selected from the group consisting of Tyr, Aph(Cbm), and Aph(Hor), and/or X4 is preferably selected from the group consisting of D-Trp and D-Aph(Cbm). 
     
     
         20 . The radiopeptide of  claim 18 , wherein the somatostatin receptor antagonist is selected from the group consisting of LM3 ([p-Cl-Phe-cyclo[D-Cys-Tyr-D-Aph(Cbm)-Lys-Thr-Cys]D-Tyr-NH 2 ]) (SEQ ID NO:2), JR11 (Cpa-cyclo[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]-D-Tyr-NH 2 ) (SEQ ID NO:3), and BASS (pNO 2 -Phe-cyclo[D-Cys-Tyr-D-Trp-Lys-Thr-Cys]D-Tyr-NH 2 ) (SEQ ID NO:4). 
     
     
         21 . The radiopeptide of  claim 1 , wherein terbium-161 is produced by neutron irradiation of gadolinium-160. 
     
     
         22 . The radiopeptide of  claim 1 , wherein terbium-161 is a non-carrier-added terbium-161 (n.c.a. terbium-161). 
     
     
         23 . The radiopeptide of  claim 1 , wherein the antagonist is preferentially taken up by tumors relative to other tissue. 
     
     
         24 . The radiopeptide of  claim 23 , wherein the ratio of radiopeptide uptake in tumor cells to radiopeptide uptake in blood is at least 50.0, the ratio of radiopeptide uptake in tumor cells to radiopeptide uptake in liver cells is at least 10.0 and/or the ratio of radiopeptide uptake in tumor cells to radiopeptide uptake in kidney cells is at least 2.0, preferably measured 2 hours after administration. 
     
     
         25 . The radiopeptide of  claim 1 , wherein the radiopeptide has the structure of the following formula: 
       
         
           
           
               
               
           
         
       
       . 
     
     
         26 . A pharmaceutical composition, comprising the radiopeptide of  claim 1  and at least one pharmaceutically acceptable excipient, preferably water. 
     
     
         27 . The pharmaceutical composition of  claim 26 , wherein the composition comprises 0.001 to 1 mg/ml or 0.01 to 1 mg/ml or 0.05 to 0.5 mg/ml radiopeptide. 
     
     
         28 . The pharmaceutical composition of  claim 26 , wherein the composition contains at least one of the group consisting of gentisic acid, ethanol, acetate, NaCl and ascorbate/ascorbic acid. 
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein the composition contains ascorbate. 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein the composition contains 0.5 mM to 0.5 M, in particular 1 mM to 100 mM or 10 mM to 100 mM ascorbate. 
     
     
         31 . The pharmaceutical composition of  claim 26 , wherein the composition has a pH value from pH 3.5 to pH 6 or from pH 4 to pH 6. 
     
     
         32 . A method of treating a disease or a tumor disease, comprising: administering a radiopeptide of  claim 1  to a subject in need of a disease treatment or tumor disease treatment. 
     
     
         33 . The method of  claim 32 , wherein the subject suffers from a neuroendocrine neoplasm and/or metastases thereof, in particular liver metastases. 
     
     
         34 . The method of  claim 32 , wherein the neoplasm is a neuroendocrine neoplasm in the gastro-pancreatic, bronchopulmonary tract, thyroid, thymus, or pituitary gland. 
     
     
         35 . The method of  claim 32 , wherein the neuroendocrine neoplasm is selected from the group consisting of: gastroenteropancreatic neuroendocrine neoplasm, neuroendocrine tumor of the lung, neuroendocrine carcinoma of the lung, in particular small cell lung cancer, thymic neuroendocrine tumor, paraganglioma, pheochromocytoma, e.g. malignant pheochromocytoma, meningioma, medullary thyroid cancer, thyroid cancer, breast cancer, renal cell carcinoma, prostate cancer, and non-Hodgkin lymphoma. 
     
     
         36 . The method of  claim 35 , wherein the neuroendocrine neoplasm is a pancreatic tumor. 
     
     
         37 . The method of  claim 33 , wherein neuroendocrine neoplasm is of Grade 1, Grade 2 or Grade 3. 
     
     
         38 . The method of  claims 33 , wherein the neuroendocrine neoplasm is stable or refractory to a therapy by Lutetium ( 177 Lu)-Oxodotreotid (Lutathera®) or other radiolabelled somatostatin analogues. 
     
     
         39 . The method of  claim 32 , wherein the radiopeptide is administered systemically, preferably intravenously.

Join the waitlist — get patent alerts

Track US2023165981A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.